Trial Profile

Comparison of the Protective Efficacy of Flublok Quadrivalent Versus Licensed Inactivated Influenza Vaccine (IIV4) in Healthy, Medically Stable Adults ≥50 Years of Age

Status: Completed

Phase of Trial: Phase III/IV

Latest Information Update: 03 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine
Indications Influenza virus infections
Focus Registrational; Therapeutic Use
Sponsors Protein Sciences Corporation

18 Nov 2020 According to a Sanofi media release, based on two phase studies (NCT02285998 and NCT02290509) the European Commission has granted a marketing authorization for Supemtek, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older.
22 Jun 2017 Results published in the New England Journal of Medicine
22 Jun 2017 Results published in a Protein Sciences Corporation media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com